Pacira BioSciences
PCRX
180 hedge funds and large institutions have $1.64B invested in Pacira BioSciences in 2017 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 43 reducing their positions, and 41 closing their positions.
188% more call options, than puts
Call options by funds: $46.7M | Put options by funds: $16.2M
91% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 43
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
5.65% more ownership
Funds ownership: 102.79% → 108.44% (+5.7%)
8% less funds holding
Funds holding: 196 → 180 (-16)
16% less capital invested
Capital invested by funds: $1.97B → $1.64B (-$322M)
34% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 41
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$55.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$34M |
| 4 |
HM
HealthCor Management
New York
|
+$31.6M |
| 5 |
PC
PointState Capital
New York
|
+$22.8M |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$87.8M |
| 2 |
Millennium Management
New York
|
-$34.9M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$33.2M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$14.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$13M |
PCRX Hedge Fund Activity: Q3 2017 in Review
180 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2017, worth a combined $1.64B — down 16% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of PCRX and 27 opened new positions — a net loss of 14 holders — while 43 trimmed existing stakes and 82 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $55.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $87.8M sold.
- 180 institutional investors held Pacira BioSciences (PCRX) as of Q3 2017, down from 196 in Q2 2017.
- Funds reported $1.64B of Pacira BioSciences stock for Q3 2017, down 16% quarter-over-quarter.
- 27 funds opened new Pacira BioSciences positions in Q3 2017 and 41 closed out, a net change of -14 holders.
- The largest Pacira BioSciences buyer in Q3 2017 was Consonance Capital Management, an estimated $55.5M added.
- The largest Pacira BioSciences seller in Q3 2017 was PFM Health Sciences, an estimated $87.8M sold.
Based on aggregated 13F filings for Q3 2017.